Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer

scientific article published in February 2018

Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.21037/JTD.2018.01.124
P932PMC publication ID5864642
P698PubMed publication ID29607153

P2093author name stringJin Wang
Jiang Zhu
Lin Zhou
Qiao Zhou
Feng Peng
Li Ren
You Lu
Yongsheng Wang
Zhenyu Ding
Meijuan Huang
Xiaojuan Zhou
Jianxin Xue
Limei Yin
Ruizhan Tong
Youling Gong
Chen Pang
Chuanfen Lei
P2860cites workSafety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerQ24633070
Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysisQ27853291
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialQ27853359
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerQ29620913
Genomic landscape of non-small cell lung cancer in smokers and never-smokersQ36851245
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung CancerQ37087884
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patientsQ38749966
Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.Q38866102
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison ProjectQ39135152
Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung CancerQ39426272
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomasQ39623256
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialQ40163779
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.Q40408396
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC StudyQ40717466
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.Q40889616
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacyQ41983246
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanomaQ45054030
Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung CancerQ47968655
A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer PatientsQ52888992
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturationQ84014638
Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up StudyQ86075907
P433issue2
P921main subjectimmunohistochemistryQ899285
P304page(s)816-824
P577publication date2018-02-01
P1433published inJournal of thoracic diseaseQ26841814
P1476titleAssessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer
P478volume10

Search more.